Hospital Pharmacy and Therapeutics Committees Are Actively Considering Forest/AstraZeneca’s Teflaro and Optimer/Cubist …

EXTON, Penn.–(BUSINESS WIRE)–Based on the 105 hospitals in this study, Teflaro has a 50 percent chance of being added to a hospital’s formulary following P&T committee review, while Dificid has a slightly higher chance of earning